|Bid||0.3600 x 0|
|Ask||0.3700 x 0|
|Day's Range||0.3600 - 0.3650|
|52 Week Range||0.3600 - 0.7000|
|Beta (5Y Monthly)||0.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 08, 2023 - Feb 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Sept 02, 1999|
|1y Target Est||1.13|
Driven by Customer Requests, Mpox Test Control Now AvailableMISSISSAUGA, Ontario, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is launching a new quality assessment product (“QAP™”) to support molecular diagnostic (“MDx”) testing for the Non-Variola Orthopoxvirus (“Mpox”), the cause of the cutaneous infection colloquially-known as “Monkeypox.” From traditional low-level inc
The analysts covering Microbix Biosystems Inc. ( TSE:MBX ) delivered a dose of negativity to shareholders today, by...
With a price-to-earnings (or "P/E") ratio of 31.1x Microbix Biosystems Inc. ( TSE:MBX ) may be sending very bearish...